Physician's Weekly
JUNE 25, 2025
WEDNESDAY, June 25, 2025 (HealthDay News) — Getting approval from your insurance company before a procedure or treatment may soon get a little easier. said this week that several of the nation’s largest health insurers have agreed to change how they handle prior authorization, a system that often causes delays in care. Kennedy Jr.
Concierge Choice Physicians
JANUARY 28, 2025
The CCP Hybrid Choice program is unique in that it offers patients the choice to join, or to remain in the traditional practice, as before. The CCP Hybrid Choice program is unique in that it offers patients the choice to join, or to remain in the traditional practice, as before. The patient decides what’s right for them.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medical Xpress
FEBRUARY 28, 2023
of high-risk hypercholesterolemia patients never achieve the low-density lipoprotein-cholesterol (LDL-C) thresholds recommended in the 2018 American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol.
FDA Law Blog
AUGUST 12, 2021
Yet, even with the first interchangeable biosimilar approval, it’s not quite clear when patients will see those savings. typically have launched with initial list prices 15% to 35% lower than comparative list prices of the reference products,” but this 15 to 35% is not a huge relief for patients given the high cost of biologics.
FDA Law Blog
JANUARY 6, 2022
Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. However, Graves’s clients were physicians/physician offices — not individual patients in need of lab services.
GeriPal
JUNE 8, 2023
When I’m on palliative care consults and attending in our hospice unit we have to counsel patients about deprescribing and de-intensifying diabetes medications. Our last podcast was with Laura Petrillo in 2018 – 5 years ago seems ancient history – though many of the points still apply today (e.g. Goldilocks zone).
FDA Law Blog
JANUARY 6, 2022
Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. However, Graves’s clients were physicians/physician offices — not individual patients in need of lab services.
Expert insights. Personalized for you.
52 
Let's personalize your content